Modular Medical (MODD) Competitors

$1.77
+0.02 (+1.14%)
(As of 05/17/2024 06:55 PM ET)

MODD vs. XAIR, CTCX, GBS, CODX, AKLI, RVP, DXR, CTSO, LNSR, and LUCD

Should you be buying Modular Medical stock or one of its competitors? The main competitors of Modular Medical include Beyond Air (XAIR), Carmell (CTCX), GBS (GBS), Co-Diagnostics (CODX), Akili (AKLI), Retractable Technologies (RVP), Daxor (DXR), Cytosorbents (CTSO), LENSAR (LNSR), and Lucid Diagnostics (LUCD). These companies are all part of the "surgical & medical instruments" industry.

Modular Medical vs.

Modular Medical (NASDAQ:MODD) and Beyond Air (NASDAQ:XAIR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

In the previous week, Modular Medical and Modular Medical both had 1 articles in the media. Beyond Air's average media sentiment score of 0.96 beat Modular Medical's score of 0.88 indicating that Beyond Air is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Modular Medical
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Beyond Air
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Modular Medical presently has a consensus price target of $4.25, indicating a potential upside of 140.11%. Beyond Air has a consensus price target of $10.75, indicating a potential upside of 684.67%. Given Beyond Air's higher possible upside, analysts clearly believe Beyond Air is more favorable than Modular Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Modular Medical
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Beyond Air
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Modular Medical has higher earnings, but lower revenue than Beyond Air. Modular Medical is trading at a lower price-to-earnings ratio than Beyond Air, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Modular MedicalN/AN/A-$13.88M-$0.97-1.82
Beyond Air$689K71.66-$55.82M-$2.13-0.64

27.5% of Modular Medical shares are owned by institutional investors. Comparatively, 31.5% of Beyond Air shares are owned by institutional investors. 32.3% of Modular Medical shares are owned by insiders. Comparatively, 19.0% of Beyond Air shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Beyond Air's return on equity of -199.90% beat Modular Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Modular MedicalN/A -235.93% -180.37%
Beyond Air N/A -199.90%-106.00%

Modular Medical has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Beyond Air has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500.

Beyond Air received 42 more outperform votes than Modular Medical when rated by MarketBeat users. However, 100.00% of users gave Modular Medical an outperform vote while only 68.75% of users gave Beyond Air an outperform vote.

CompanyUnderperformOutperform
Modular MedicalOutperform Votes
2
100.00%
Underperform Votes
No Votes
Beyond AirOutperform Votes
44
68.75%
Underperform Votes
20
31.25%

Summary

Beyond Air beats Modular Medical on 9 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MODD vs. The Competition

MetricModular MedicalSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$38.76M$3.99B$5.37B$7.98B
Dividend YieldN/A1.96%44.70%3.91%
P/E Ratio-1.8216.66139.1318.77
Price / SalesN/A65.022,368.3485.85
Price / CashN/A47.4336.9831.98
Price / Book3.855.265.514.64
Net Income-$13.88M$4.48M$106.10M$217.28M
7 Day Performance2.91%2.00%1.42%2.90%
1 Month Performance8.59%4.45%4.97%6.66%
1 Year Performance71.84%16.45%7.98%9.89%

Modular Medical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XAIR
Beyond Air
3.5618 of 5 stars
$1.14
+1.8%
$10.75
+843.0%
-76.3%$40.36M$689,000.00-0.5498Gap Up
CTCX
Carmell
0 of 5 stars
$2.17
-0.5%
N/AN/A$41.76MN/A0.009Gap Down
GBS
GBS
0 of 5 stars
$2.39
-0.8%
N/A-23.9%$35.59M$440,000.00-4.277Gap Down
CODX
Co-Diagnostics
3.4406 of 5 stars
$1.12
+4.7%
$2.00
+78.6%
-21.0%$35.03M$6.81M-0.85155
AKLI
Akili
2.6077 of 5 stars
$0.45
+2.3%
$4.00
+797.5%
-67.3%$35.03M$1.68M-0.5968Earnings Report
RVP
Retractable Technologies
0 of 5 stars
$1.12
+0.9%
N/A-16.4%$33.53M$43.60M-4.67148Earnings Report
Analyst Forecast
News Coverage
DXR
Daxor
0 of 5 stars
$9.40
flat
N/AN/A$44.51M$1.28M0.00N/APositive News
CTSO
Cytosorbents
0.978 of 5 stars
$0.83
flat
$2.50
+200.6%
-70.9%$45.16M$36.35M-1.41186Analyst Forecast
Analyst Revision
LNSR
LENSAR
2.6099 of 5 stars
$3.97
+3.7%
$8.00
+101.5%
+64.1%$45.26M$42.16M-2.51130
LUCD
Lucid Diagnostics
1.6795 of 5 stars
$0.93
-2.1%
$2.75
+196.1%
-42.7%$46.23M$2.43M-0.7370Analyst Revision
Gap Up

Related Companies and Tools

This page (NASDAQ:MODD) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners